Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 15/20 | 0.65 |
| ▸ | PGR | P06401 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.61 |
| ▸ | DRD1 | P21728 | 1/20 | 0.61 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.61 |
| ▸ | FPR3 | P25089 | 1/20 | 0.61 |
| ▸ | PDE4A | P27815 | 1/20 | 0.61 |
| ▸ | GPR183 | P32249 | 1/20 | 0.61 |
| ▸ | DRD3 | P35462 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.61 |
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351640 | 1.00 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16303344 | 0.90 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15057950 | 0.90 | P2RY12 (0.65) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15846303 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15048854 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15859655 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15859674 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL16800343 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL15859666 | 0.89 | P2RY12 (0.64) | P2RY12PGRADORA3CHRM1DRD1 | |
| SCHEMBL24080706 | 0.86 | P2RY12 (0.50) | P2RY12PGRADORA3CHRM1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250235455-A1 | AQUEOUS TICAGRELOR SOLUTIONS, METHOD OF MANUFACTURING AND USES | HYLORIS DEVELOPMENTS SA (BE) | 2025-07-24 | — | — | US | disclosed |
| WO-2023222184-A1 | AQUEOUS TICAGRELOR SOLUTION, METHOD OF MANUFACTURING AND USES | HYLORIS DEVELOPMENTS SA (BE) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023222660-A1 | AQUEOUS TICAGRELOR SOLUTIONS, METHOD OF MANUFACTURING AND USES | HYLORIS DEVELOPMENTS SA (BE) | 2023-11-23 | — | — | WO | disclosed |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2023-10-03 | — | — | US | disclosed |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LTD (GB) | 2021-12-02 | — | — | US | disclosed |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2021-03-23 | — | — | US | disclosed |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2019-11-26 | — | — | US | disclosed |
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2019-03-14 | — | — | US | disclosed |
| US-9982061-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-9982061-B2 | Antibodies to ticagrelor and methods of use | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160130366-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| US-20160130366-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2016-05-12 | — | — | US | disclosed |
| WO-2016050867-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | MEDIMMUNE LIMITED (GB) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077882-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20250235455-A1 | AQUEOUS TICAGRELOR SOLUTIONS, METHOD OF MANUFACTURING AND USES | PTGES, TTPA, PTGIS | P2RY12 12/4885PGR 1046/4885ADORA3 144/4885 |
| US-10954308-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-11773186-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20210371546-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-20160130366-A1 | ANTIBODIES TO TICAGRELOR AND METHODS OF USE | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
| US-10487154-B2 | Antibodies to ticagrelor and methods of use | NT5C2, GP6, P2RY6 | P2RY12 9/4885PGR 500/4885ADORA3 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.